IA
VRDN icon

IFP Advisors’s Viridian Therapeutics VRDN Stock Holding History

IFP Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$184 Hold
10
– – ﹤0.01% 4866
2026
Q1 		$196 Hold
10
– – ﹤0.01% 4622
2025
Q4 		$311 Hold
10
– – ﹤0.01% 4394
2025
Q3 		$216 Buy
+10
New +$180 ﹤0.01% 4385
2025
Q2 		– Hold
0
– – – 3548
2025
Q1 		– Hold
0
– – – 3830
2024
Q4 		– Hold
0
– – – 3715

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

IFP Advisors's VRDN Position: Q2 2026 in Review

IFP Advisors held its Viridian Therapeutics (VRDN) position steady in Q2 2026 at 10 shares worth $184. The position accounts for ﹤0.01% of the portfolio, ranked #4866.

IFP Advisors first reported a position in VRDN in Q3 2025 and has held it in 4 quarters since. The position peaked at $311 in Q4 2025. 212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • IFP Advisors held 10 shares of Viridian Therapeutics worth $184 as of Q2 2026.
  • IFP Advisors left its Viridian Therapeutics share count unchanged in Q2 2026.
  • Viridian Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #4866 holding.
  • IFP Advisors first reported a position in Viridian Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • IFP Advisors's Viridian Therapeutics position peaked at $311 in Q4 2025.
  • 212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.